This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Fuster, V. Articles by Gotto, A. M. Search for Related Content PubMed PubMed Citation Articles by Fuster, V. Articles by Gotto, A. M., Jr Pubmed/NCBI databases Medline Plus Health Information Coronary Artery Disease Related Collections Health policy and outcome research Lipids Primary prevention Pathophysiology

(Circulation. 2000;102:IV-94.)
© 2000 American Heart Association, Inc.

Special Anniversary Issue

Risk Reduction

Valentin Fuster, MD, PhD; Antonio M. Gotto, Jr, MD, DPhil

From Mt Sinai Medical Center (V.F.) and Weill Medical College of Cornell University (A.M.G.), New York, NY.

Correspondence to Antonio M. Gotto, Jr, c/o Mr Jesse Jou, Weill Medical College of Cornell University, 445 E 69th St, Olin Hall 205, New York, NY 10021. E-mail amg_editorial@med.cornell.edu

Key Words: prevention • atherosclerosis • lipids • pathology

In the 1950s, atherosclerosis, the disease process underlying coronary heart disease (CHD), was considered an inevitable, irreversible, and degenerative consequence of aging. Today we understand that coronary disease is treatable, that atherosclerotic plaque progression may be stabilized, and that prevention through risk factor modification can yield significant clinical benefits.

Because atherosclerosis develops silently over several decades and begins as early as young adulthood,¹ most investigators foresee a blurring of the distinction between primary and secondary prevention in the new millennium. However, asymptomatic patients may be unaware of their atherosclerotic burden and may undervalue the impact of an unfavorable risk profile.^{2 3} At the same time, physicians, concerned by a healthcare environment in flux, receive the consistent message that secondary prevention is the most cost-effective means of management.⁴ However, waiting until the patient has experienced a coronary event before intervening raises troublesome ethical concerns that must be addressed before excluding primary prevention altogether. Treatment of coronary risk factors is not as vigorous as it must be. For example, many physicians do not treat lipid disorders to the goals established by national guidelines.⁵

Although invasive revascularization procedures are sophisticated and may alleviate the physical symptoms of obstructive plaque and may improve survival in some patients with more severe disease,⁶ the majority of clinical coronary events arise from lesions that may be angiographically invisible and only moderately stenotic.⁷ Therefore, traditional interventional cardiology can only be part of the solution to the toll of cardiovascular disease. As we enter the 21st century, there is a . . . [Full Text of this Article]